Bioidentical Hormone Replacement Therapy: What the Evidence Actually Says

Prepared by Daniel Soule
Director, HormoneSynergy® Clinic LLC
Portland & Lake Oswego, Oregon | USA

Bioidentical hormone replacement therapy has become unnecessarily confusing because the discussion is often shaped by people selling either fear or certainty.

The fear largely traces back to the way the Women’s Health Initiative was communicated after its initial findings were released in 2002. The certainty comes from the opposite direction, where hormone therapy is sometimes marketed as an answer to weight gain, fatigue, mood changes, libido, skin aging, cognitive decline and longevity itself.

Neither approach reflects contemporary hormone medicine.

Hormonal changes can cause substantial symptoms and can affect bone, reproductive tissue, sleep, sexual health and quality of life. Hormone therapy can be highly effective when there is a clear indication and an appropriate benefit-risk profile. It can also cause harm when the patient is poorly selected, the dose is excessive, the formulation or route is inappropriate, or follow-up is inadequate.

At HormoneSynergy®, bioidentical hormone therapy has been part of clinical care for more than two decades. Its continued use is not based on the current popularity of menopause medicine. It reflects the longstanding clinical recognition that appropriately prescribed hormone therapy can be an important part of care for selected women and men.

It remains one part of that care rather than the foundation of it.

What “bioidentical” actually means

The term bioidentical describes molecular structure. A bioidentical hormone has the same chemical structure as the corresponding hormone produced by the human body.

That definition does not indicate whether a medication is FDA-approved or compounded, whether it is derived from a plant or synthesized in a laboratory, whether its dose is appropriate, or whether it is safer for a particular patient.

FDA-approved estradiol patches, gels, sprays, vaginal preparations and oral micronized progesterone are examples of bioidentical hormone medications. Compounded estradiol, progesterone and testosterone can also be bioidentical in molecular structure, but compounded medications belong to a separate regulatory and quality-control category.

Conjugated equine estrogens such as Premarin® contain estrogens originally derived from pregnant mare urine and are not identical to the primary estrogen produced by the human ovary. Medroxyprogesterone acetate, sold as Provera®, is a synthetic progestin rather than progesterone. Methyltestosterone is a synthetic oral androgen and should not be confused with physiologic testosterone replacement.

The terms natural, bioidentical, FDA-approved and compounded therefore describe different characteristics of a medication and should not be used interchangeably.

Hormone therapy works within a larger health framework

Hormone replacement can improve important symptoms, but it cannot compensate for untreated sleep apnea, poor metabolic health, inadequate nutrition, loss of muscle, excessive alcohol intake, uncontrolled blood pressure, thyroid disease, iron or vitamin deficiencies, cardiovascular disease or chronic sleep deprivation.

For that reason, HormoneSynergy® evaluates hormone therapy within the broader context of healthspan. Attention to sleep, nutrition, adequate protein, resistance training, glucose regulation, stress physiology, body composition, cardiovascular risk, thyroid function and nutrient status continues whether hormones are prescribed or not.

A woman experiencing severe vasomotor symptoms, insomnia, declining bone density and genitourinary symptoms may obtain substantial benefit from menopausal hormone therapy. A man with repeatedly confirmed testosterone deficiency accompanied by compatible symptoms may benefit from testosterone replacement. Those therapies still belong within comprehensive medical care rather than functioning as substitutes for it.

What the Women’s Health Initiative actually taught medicine

The Women’s Health Initiative changed hormone prescribing almost overnight after results from one of its hormone trials were reported in 2002. Public messaging quickly condensed a complicated body of evidence into the idea that menopausal hormone therapy caused breast cancer, heart disease, stroke, blood clots and dementia.

The WHI remains an important body of research, but its findings cannot be applied indiscriminately to every hormone, every formulation, every route of administration and every woman seeking treatment today.

The most influential combined-hormone trial evaluated oral conjugated equine estrogens together with medroxyprogesterone acetate. Participants included women who were considerably older and further from the menopausal transition than many patients who currently begin treatment for menopausal symptoms.

Subsequent analyses and later studies have made the clinical picture more nuanced. Age at initiation matters. Time since menopause matters. Estrogen alone and estrogen combined with a progestogen do not have identical risk profiles. Micronized progesterone and synthetic progestins are not pharmacologically identical. Oral and transdermal estrogen have different effects on hepatic physiology.

The appropriate lesson from the WHI is not that hormone therapy is universally dangerous or universally safe. It is that the benefit-risk calculation depends on the treatment and the patient receiving it.

Modern menopause guidance is based on individualization

The Menopause Society identifies menopausal hormone therapy as the most effective treatment for vasomotor symptoms such as hot flashes and night sweats and recognizes its effectiveness for genitourinary syndrome of menopause and prevention of bone loss and fracture.

For many healthy women with bothersome menopausal symptoms who begin treatment before age 60 or within approximately 10 years of menopause onset, the benefit-risk profile is generally more favorable than it is when systemic therapy is first initiated substantially later in life. This is not an automatic prescribing rule; it is one component of risk assessment.

Route and dose are also part of that assessment. The Menopause Society notes that the risk of blood clots is increased with oral hormone therapy. Nonoral routes become particularly relevant when cardiovascular or thrombotic risk factors are present.

Estrogen: the route of administration matters

Discussions of menopausal hormone therapy frequently refer to “estrogen” as though every estrogen preparation has the same pharmacology. It does not.

Estradiol may be administered orally, through a transdermal patch, gel or spray, weekly injections, subcutaneous pellets, by vaginal preparations, and through other selected routes. Conjugated equine estrogens, estradiol and estriol are also different molecules. Their clinical effects cannot be assumed to be identical simply because all fall under the broad category of estrogen therapy.

Oral estrogen is absorbed through the gastrointestinal tract and reaches the liver through the portal circulation before entering the systemic circulation. This first-pass hepatic exposure can influence coagulation proteins, triglycerides, inflammatory markers and binding proteins. This pharmacology has helped explain why oral estrogen has historically demonstrated a less favorable venous thromboembolic profile than transdermal estradiol.

Transdermal estradiol enters the systemic circulation through the skin and largely avoids first-pass hepatic metabolism. This distinction is not new. It has influenced hormone prescribing for decades and is one reason transdermal estradiol has often been favored when thrombotic, metabolic or cardiovascular considerations are relevant.

What the 2026 Danish study adds

A nationwide nested case-control study published in BMJ on September 23, 2026 added contemporary evidence to this longstanding route-of-administration discussion. Investigators examined menopausal hormone therapy and venous thromboembolism, ischemic stroke and myocardial infarction using Danish health registry data.

Compared with nonuse, oral menopausal hormone therapy was associated with increased venous thromboembolic risk across the doses and treatment durations studied. Increased risk of ischemic stroke and myocardial infarction was more dependent on oral dose and duration, with the clearest associations occurring with higher-dose oral therapy and longer exposure.

Transdermal therapy was not associated with increased venous thromboembolism, ischemic stroke or myocardial infarction across the dose categories examined. An exception was an observed association with myocardial infarction among women using a transdermal combined cyclic regimen, although the investigators noted that the estimate was based on relatively sparse data.

The distinction in wording is important. This was an observational registry study. It does not prove that transdermal estradiol carries no cardiovascular or thrombotic risk under every circumstance. It does, however, provide additional contemporary evidence consistent with the biological and clinical distinction between oral and transdermal estrogen.

It also reinforces a principle that has been part of HormoneSynergy® hormone prescribing for approximately 25 years: the route of estrogen administration is a clinical decision, not a cosmetic preference. Transdermal patches and other nonoral approaches have long been used when appropriate because avoiding first-pass hepatic exposure can be clinically meaningful.

Vaginal estrogen is a different clinical discussion

Low-dose vaginal estrogen is commonly used for genitourinary syndrome of menopause, including vaginal dryness, painful intercourse, urinary urgency, recurrent urinary symptoms and tissue fragility related to estrogen deficiency.

Systemic absorption from appropriately dosed local vaginal estrogen is generally low, although absorption varies by product, dose and vaginal tissue condition. Local vaginal therapy therefore should not automatically be placed in the same risk category as systemic estrogen treatment.

Some women with genitourinary symptoms need local treatment without systemic hormone therapy at all.

Progesterone is not the same as every progestogen

Women with a uterus who receive systemic estrogen generally require adequate endometrial protection. Unopposed systemic estrogen can stimulate the endometrium and increase the risk of endometrial hyperplasia and cancer.

Micronized progesterone is structurally identical to endogenous progesterone. Medroxyprogesterone acetate and other synthetic progestins are different molecules with different pharmacologic characteristics. Evidence suggests that progestogen choice may influence breast, vascular and metabolic outcomes, although comparative evidence is not equally strong for every outcome.

Oral micronized progesterone may also have sedating effects through neuroactive metabolites and can improve sleep in some women. Others experience morning sedation, dizziness, mood changes or other adverse effects. Dose, timing and regimen may need adjustment.

Progesterone should therefore be selected for its clinical purpose rather than treated as an incidental addition to estrogen therapy.

Testosterone in women: a narrower evidence base than the marketing suggests

Women produce testosterone throughout adult life, and circulating androgen concentrations generally decline with age. That physiology is sometimes used to justify testosterone for a wide range of symptoms, but the evidence is considerably narrower than many wellness advertisements imply.

The best-established evidence-based indication for systemic testosterone therapy in postmenopausal women is hypoactive sexual desire disorder after appropriate biopsychosocial assessment. International consensus guidance and the International Society for the Study of Women’s Sexual Health support carefully dosed testosterone in appropriately selected women for this indication.

Evidence is not sufficient to prescribe testosterone routinely for cognitive enhancement, prevention of dementia, general fatigue, weight loss, depression, muscle building or anti-aging. Those symptoms deserve evaluation for other common contributors including sleep disturbance, iron deficiency, thyroid disease, inadequate nutrition, medication effects, pain, relationship factors, metabolic disease and mood disorders.

When testosterone is used in women, dosing should remain within the physiologic female range. Monitoring is intended to avoid supraphysiologic exposure and adverse effects.

The goal is not to create a laboratory-defined “optimal” testosterone level. Treatment should have a defensible indication, measurable clinical benefit and an appropriate safety plan.

Testosterone in men: replacement begins with diagnosis

Testosterone therapy in men should begin with compatible symptoms and appropriately confirmed biochemical deficiency rather than an isolated laboratory value or a desire to increase performance.

Evaluation may include repeat morning testosterone measurement, free testosterone or SHBG when appropriate, LH and FSH, prolactin when indicated, thyroid function, medication review, sleep apnea risk, alcohol use, metabolic health, body composition, fertility goals, hematocrit and prostate assessment.

For men with confirmed hypogonadism, testosterone therapy can improve sexual symptoms and may improve bone density, anemia and body composition in selected patients. Treatment also suppresses spermatogenesis and may increase hematocrit, and it requires ongoing clinical and laboratory monitoring.

Men seeking testosterone deserve medical evaluation rather than a prescribing model built around achieving a predetermined “optimal” number.

Pellets: convenience has tradeoffs

Hormone pellets appeal to some patients because they provide prolonged delivery without daily or weekly administration. That convenience should be weighed against a significant practical limitation: once a pellet has been inserted, its dose cannot readily be reduced or discontinued.

If exposure proves excessive or adverse effects develop, those effects may persist while the pellet continues releasing hormone. Dose titration is therefore less flexible than with patches, gels, oral medication or many injectable regimens.

Pellets may have a role for selected patients, but convenience alone does not establish clinical superiority.

Compounded hormones: useful in selected circumstances

Compounded hormone medications can be valuable when a patient requires a dose, formulation, excipient profile or route that is not available in an appropriate FDA-approved product.

Compounding does not inherently make a hormone safer, cleaner or more biologically appropriate. It introduces additional considerations involving potency, formulation consistency, sterility when applicable, ingredient sourcing, pharmacy quality and regulatory oversight.

At HormoneSynergy®, FDA-approved products are used when they appropriately meet the clinical need. Compounded medications may be considered when meaningful individualization is necessary, using reputable compounding pharmacies and appropriate prescribing standards.

Hormone testing has a role, but it does not replace clinical judgment

Laboratory testing can help clarify endocrine disorders, establish baseline safety information and monitor selected therapies. Its usefulness depends on what is being measured, why it is being measured and whether the result changes management.

Menopause itself is usually diagnosed clinically in women of the appropriate age and menstrual history rather than by repeatedly measuring estradiol or FSH. Laboratory testing becomes more useful when the diagnosis is uncertain, symptoms are atypical, premature ovarian insufficiency is possible, androgen therapy is being considered, or another endocrine condition may be contributing.

Follow-up testing may also help identify excessive hormone exposure or treatment-related changes in hematocrit, lipids, liver function or other relevant parameters.

No laboratory test substitutes for the patient’s symptoms, medical history, physical findings and clinical risk assessment.

Breast cancer risk requires a more precise discussion

Breast cancer remains one of the most important concerns patients raise when considering menopausal hormone therapy. A useful discussion requires more than saying that hormone therapy either causes or does not cause breast cancer.

Risk varies with the type of therapy, duration of exposure, whether estrogen is given alone or with a progestogen, the progestogen used, baseline breast risk and the individual patient’s history.

Women who have undergone hysterectomy and can use estrogen without a progestogen are not in the same treatment category as women with a uterus who require endometrial protection. Personal history of hormone-sensitive breast cancer requires a substantially different discussion from average-risk menopause treatment.

Family history, breast density, prior biopsies, alcohol intake, obesity, metabolic health, genetics when appropriate and adherence to recommended breast screening all belong in the assessment.

Neither fear nor blanket reassurance constitutes informed consent.

Cardiovascular health should be evaluated independently

Menopausal hormone therapy should not be prescribed as a substitute for cardiovascular prevention.

Blood pressure, apoB or other measures of atherogenic particle burden, Lp(a), triglycerides, glucose regulation, smoking, visceral adiposity, sleep apnea, exercise capacity, family history and established vascular disease continue to matter whether a woman uses estrogen or not.

Hormonal physiology can affect vascular function, lipids, insulin sensitivity and body composition, but those effects do not make estrogen a statin, an antihypertensive medication or a treatment for established coronary atherosclerosis.

The cardiovascular context also influences hormone decisions. Beginning treatment in a healthy symptomatic woman around the menopausal transition is different from initiating systemic estrogen for the first time decades later in a patient with established vascular disease.

This is one reason HormoneSynergy® integrates menopausal care with preventive cardiovascular assessment rather than treating the two as unrelated disciplines.

Bone health remains an important benefit

Estrogen deficiency accelerates bone resorption after menopause and contributes to declining bone mineral density and fracture risk. Menopausal hormone therapy prevents bone loss and reduces fracture risk while it is being used.

Bone care nevertheless extends beyond estrogen. DEXA findings, fracture history, muscle mass, protein intake, vitamin D and calcium status, resistance training, balance, fall risk, thyroid and parathyroid disorders, gastrointestinal absorption, medication exposures and alcohol use may all influence fracture risk.

A patient with osteoporosis deserves a complete fracture-risk strategy rather than a single intervention presented as the entire answer.

Brain, mood and sleep symptoms deserve clinical context

Changes in sleep, mood, attention, memory and word retrieval are common during the menopausal transition. Fluctuating estrogen, vasomotor symptoms and sleep disruption can all contribute.

Hormone therapy may improve sleep indirectly by treating hot flashes and night sweats, and selected women experience improvement in mood symptoms occurring around the menopausal transition. These benefits should not be expanded into claims that hormone therapy prevents dementia or reverses cognitive aging.

Persistent cognitive symptoms deserve a broader evaluation that may include sleep quality and sleep apnea, blood pressure, vascular risk, glucose regulation, thyroid status, medication effects, alcohol exposure, depression or anxiety, hearing, physical activity, nutrient deficiencies and other neurologic or medical causes.

Genitourinary syndrome of menopause is common and frequently undertreated

Declining estrogen can produce vaginal dryness, burning, painful intercourse, urinary urgency, recurrent urinary symptoms and progressive tissue fragility. Many women do not volunteer these symptoms unless clinicians ask directly.

Low-dose vaginal estrogen is one of the most effective treatments for genitourinary syndrome of menopause. Depending on the preparation and clinical circumstances, it can often be used independently of systemic menopausal hormone therapy.

This distinction is clinically useful because some patients whose primary symptoms are vaginal or urinary may not require systemic estrogen at all.

Who requires additional caution?

Hormone therapy may be inappropriate, temporarily inappropriate or require specialist input in patients with particular medical histories. Examples include:

• Personal history of hormone-sensitive breast cancer
• Unexplained postmenopausal bleeding
• Known or suspected estrogen-dependent malignancy
• Active or recent venous thromboembolism
• Known high-risk thrombophilia
• Previous stroke or significant cardiovascular disease
• Active liver disease
• Untreated endometrial hyperplasia
• Pregnancy
• Severely uncontrolled hypertension
• Complex neurologic or migraine history requiring additional assessment
• Untreated significant sleep apnea when testosterone therapy is being considered
• Current fertility goals in men considering testosterone therapy

These conditions do not all carry the same level of risk and should not be interpreted as an interchangeable list of absolute contraindications. They are reasons for individualized medical assessment and, when appropriate, collaboration with gynecology, oncology, cardiology, hematology or another specialist.

Postmenopausal bleeding requires evaluation

Any new bleeding after menopause should be medically evaluated.

Bleeding can result from benign causes including polyps, fibroids, vaginal or endometrial atrophy, infection and hormone-related endometrial changes. It can also be associated with endometrial hyperplasia or malignancy.

Hormone therapy does not remove the need to investigate unexpected postmenopausal bleeding.

The HormoneSynergy® approach

Hormone decisions at HormoneSynergy® begin with the patient rather than with a predetermined protocol.

The assessment considers the nature and timing of symptoms, menopausal stage, medical and family history, cardiovascular and thrombotic risk, breast and uterine health, metabolic status, bone health, medications, laboratory findings when relevant and the patient’s priorities.

From there, the clinical questions become practical. Is hormone therapy indicated? Which hormone is needed? What route provides the appropriate balance of benefit and risk? Is an FDA-approved formulation suitable? Is there a genuine reason to compound? What dose is likely to accomplish the treatment goal without unnecessary exposure? What needs to be monitored?

Hormone therapy should not be used to promise reversal of aging, prevention of dementia, prevention of cardiovascular disease or a dramatic transformation in every patient. It should be used when the expected clinical benefit justifies the risk and when that treatment can be monitored responsibly.

Monitoring is part of the prescription

Follow-up depends on the therapy and the patient but may include review of symptoms and adverse effects, blood pressure, body composition, relevant hormone concentrations, complete blood count, metabolic and cardiovascular markers, thyroid testing, breast screening, gynecologic evaluation when indicated, DEXA monitoring, sleep apnea assessment and prostate or hematocrit monitoring in men receiving testosterone.

The purpose of monitoring is not to chase laboratory targets. It is to determine whether treatment is helping, whether exposure remains appropriate and whether new safety concerns have appeared.

Common questions about BHRT

Are bioidentical hormones automatically safer?

No. Molecular similarity to a human hormone does not eliminate pharmacologic risk. Dose, route, formulation, medical history and monitoring remain important.

Are compounded hormones better than FDA-approved hormones?

Not inherently. Compounding can be useful when individualized dosing or formulation is clinically necessary. When an FDA-approved medication adequately meets the patient's needs, its standardized manufacturing and regulatory oversight are advantages.

Do oral and transdermal estrogen have the same thrombotic risk?

Available evidence indicates meaningful differences. Oral estrogen undergoes first-pass hepatic metabolism and has been associated with greater venous thromboembolic risk. Transdermal estradiol largely avoids that hepatic first-pass exposure and has generally shown a more favorable thrombotic profile. The 2026 Danish BMJ study found no increased thrombotic risk associated with transdermal therapy in the study population, although observational evidence should not be interpreted as proof of zero risk.

Does every woman who uses estrogen need progesterone?

Women with a uterus generally require adequate endometrial protection when using systemic estrogen. Low-dose local vaginal estrogen is a different clinical situation and often does not require systemic progesterone, depending on the product and individual circumstances.

Should hormone therapy automatically stop at age 60 or 65?

No universal age cutoff applies to every patient. Continued therapy may be reasonable for selected women after reassessment of symptoms, treatment goals and changing medical risks.

Is hormone therapy only useful for hot flashes?

No. Menopausal hormone therapy may also address night sweats, genitourinary syndrome and prevention of bone loss and fracture. Individual symptoms and treatment goals determine whether systemic or local therapy is appropriate.

Is hormone therapy an anti-aging treatment?

Hormone therapy can restore deficient or declining hormonal function and improve clinically meaningful symptoms in selected patients. Current evidence does not justify presenting it as a treatment that reverses biological aging.

The bottom line

Bioidentical hormone therapy occupies a legitimate place in modern medicine. Estradiol, progesterone and testosterone are pharmacologically active hormones that can produce substantial benefit when prescribed for appropriate indications.

The same fact requires that they be used thoughtfully.

The meaningful clinical question is not whether hormone therapy is categorically good or bad. It is whether a particular hormone is appropriate for a particular patient at a particular point in life, using a formulation, route and dose that fit the treatment goal and the patient's risk profile.

That is the standard by which hormone therapy should be judged.

Selected References

• Berggreen J, et al. Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study. BMJ. 2026;394:e100688.
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022.
• The Menopause Society. Position Statements and Professional Resources.
• ACOG Clinical Consensus: Compounded Bioidentical Menopausal Hormone Therapy.
• Canonico M, et al. ESTHER Study: route of estrogen administration and venous thromboembolism risk.
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration.
• International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.

Related HormoneSynergy® Resources

Explore additional evidence-based articles on menopause, hormone therapy, preventive cardiology, metabolic health, bone health and healthy aging in the HormoneSynergy® Longevity Medicine Resource Library.

Editorial Transparency

This article was prepared by HormoneSynergy® Clinic for patient education. It reflects current clinical guidance, peer-reviewed medical literature and clinical experience. Observational research is identified as such and should not be interpreted as proving causation. Areas in which evidence remains limited or evolving should be discussed with a qualified clinician. This information is not a substitute for individualized medical care.